About Transmembrane protein 79
Transmembrane protein 79 (TMEM79) is a protein
from Homo sapiens identified by UniProt accession
Q9BSE2, 394 residues long.
MolForge cross-references it against 0 known binders and
285 disease associations.
Target properties
| Protein name | Transmembrane protein 79 |
|---|
| UniProt accession | Q9BSE2 |
|---|
| Gene | TMEM79 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 394 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (285)
Diseases linked to this target (Open Targets).
- mean corpuscular hemoglobin concentration · score 0.13
- HbA1c measurement · score 0.12
- mean corpuscular volume · score 0.11
- basophil count · score 0.11
- hemoglobin measurement · score 0.10
- uncombable hair syndrome · score 0.10
- erythrocyte count · score 0.09
- red blood cell density measurement · score 0.09
- serum albumin measurement · score 0.09
- Alopecia universalis · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BSE2-F1 | alphafold | PREDICTED | 61.13 | — |
Amino-acid sequence (394 residues)
MTEQETLALL EVKRSDSPEK SSPQALVPNG RQPEGEGGAE SPGAESLRVG SSAGSPTAIE GAEDGLDSTV SEAATLPWGT GPQPSAPFPD PPGWRDIEPE PPESEPLTKL EELPEDDANL LPEKAARAFV PIDLQCIERQ PQEDLIVRCE AGEGECRTFM PPRVTHPDPT ERKWAEAVVR PPGCSCGGCG SCGDREWLRA VASVGAALIL FPCLLYGAYA FLPFDVPRLP TMSSRLIYTL RCGVFATFPI VLGILVYGLS LLCFSALRPF GEPRREVEIH RRYVAQSVQL FILYFFNLAV LSTYLPQDTL KLLPLLTGLF AVSRLIYWLT FAVGRSFRGF GYGLTFLPLL SMLMWNLYYM FVVEPERMLT ATESRLDYPD HARSASDYRP RPWG
Explore Transmembrane protein 79 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets